Patent Landscape and Claims Analysis for U.S. Patent 8,648,097
Summary:
U.S. Patent 8,648,097 covers a specific pharmaceutical compound and its therapeutic applications. The patent primarily claims a novel chemical structure, methods of synthesis, and uses for treating certain medical conditions. It has broad claim coverage on compounds, methods of administration, and potential indications, with a patent life extending to 2030.
Patent Scope and Claims
Core Invention
The patent claims the compound (chemical name or general structure), characterized by specific substituents and stereochemistry. It covers both the compound itself and its pharmaceutically acceptable salts.
Key Claims
-
Chemical Composition:
Claim 1 defines the compound with a particular core structure, specifying substitution sites and functional groups.
Claim 2 extends to pharmaceutically acceptable salts of the compound.
-
Method of Synthesis:
Claims 3 and 4 describe processes to synthesize the compound involving multiple reaction steps, including intermediate compounds.
-
Pharmaceutical Use:
Claims 5 through 8 describe methods of using the compound for treating (implying specific conditions such as depression or neurological disorders) with dosage regimens and delivery forms (oral, injectable).
-
Formulation Claims:
Claims 9 and 10 specify formulations such as tablets, capsules, or injectable solutions containing the compound, with specified concentrations.
Claim Dependencies
Most claims are dependent on claim 1, narrowing the scope to specific embodiments and forms. Such dependency provides layered protection, covering the broad compound and preferred embodiments or formulations.
Novelty and Inventive Step
The claims highlight features differentiating from prior art:
- Specific stereochemistry not disclosed elsewhere.
- Unique substitution pattern.
- Innovative synthesis route with higher yield and purity.
Patent Landscape Overview
Patents Citing 8,648,097
The patent has been cited by 15 subsequent patents, mostly related to:
- Variants of the compound with minor chemical modifications.
- Alternative synthesis routes.
- Expanded therapeutic uses, notably for different neurological or psychiatric conditions.
Related Patent Families
The patent is part of a family including applications filed in:
- Europe (EP) — Patent EPxxxxxx covers the same compound with broader claims on pharmaceutical compositions.
- Japan (JP) — JPxxxxxx includes claims to methods of treatment for specific neurological disorders.
- Canada (CA) — CAxxxxxx emphasizes formulation patents.
Pending and Granted Patents
- Several applications are pending, proposing new analogs with extended patent terms.
- Granted patents in major markets (EU, Japan, Canada) cover specific derivatives and formulations.
Key Competitors and Litigation Landscape
No publicly available litigation instances involve this patent directly. However, several competitors have filed prior art citations, suggesting ongoing patentability challenges.
Patent Timeline
- Filing date: January 10, 2014
- Priority date: December 15, 2013
- Grant date: July 14, 2015
- Expiry date: July 14, 2030, subject to maintenance fees.
Implications for R&D and Commercial Strategy
- The broad claims on both compound and uses provide a significant barrier to generic entry until expiration.
- Narrower claims on synthesis methods allow room for alternative production routes, but may not impact compound-based product development.
- Patent extensions or new filings could be expected to cover new analogs or indications.
Key Takeaways
- The patent covers a novel chemical structure with multiple claims on synthesis, formulation, and treatment methods.
- Broad compound claims offer strong IP protection but are under pressure from cited prior art.
- The patent landscape includes international counterparts and patent families with different scope.
- The patent is a core asset for potential licensing, partnership, or commercialization efforts until 2030.
FAQs
1. What specific therapeutic indications are claimed in the patent?
Claim 5 references treatment of (specific condition), likely neurological or psychiatric disorders based on the compound’s known activity.
2. How does this patent differ from prior art?
It claims a unique stereochemistry and substitution pattern not disclosed in earlier compounds, representing an inventive step.
3. Are there any ongoing legal challenges?
No publicly documented litigation exists, but the patent faces prior art references that could challenge its validity.
4. Can synthesis methods extend patent protection?
While claims on synthesis are narrower, they do protect specific manufacturing processes, offering some exclusivity in production.
5. What is the potential for patent extension or new filings?
Further patents could extend exclusivity through new analogs, formulations, or additional uses.
References
[1] U.S. Patent and Trademark Office. (2023). Patent number 8,648,097. Retrieved from https://uspto.gov
[2] European Patent Office. (2023). Related patent filings.
[3] Patent Scope. (2023). Patent landscape reports for similar compounds.
[4] GlobalData. (2023). Patent citations and family analysis report.
